To see all protocols that comply with the WHO Essential Medicine List 

Prognostic factors and risk stratification for survival in patients with metastatic renal cell carcinoma (RCC).

The two most commonly utilised prognostic scoring systems for defining risk groups in patients with metastatic RCC are the Memorial Sloan Kettering Cancer Center (MSKCC) modelr,r and the International Metastatic RCC Database Consortium (IMDC) model,r,r colloquially known as the 'Motzer' and 'Heng' score respectively. The models separate patients into three distinct risk groups (favourable/intermediate/poor) with varying survival rates.

Note: The model does not address differences in histology.

MSKCCr
prognostic factors

IMDCr
prognostic factors

Karnofsky performance score Less than 80% Karnofsky performance score Less than 80%
Time from diagnosis to systemic treatment Less than 12 months Time from diagnosis to systemic treatment Less than 12 months
Haemoglobin Less than lower limit of laboratory reference range Haemoglobin Less than lower limit of laboratory reference range
Corrected serum calcium Greater than 2.5 mmol/L Corrected serum calcium Greater than upper limit of laboratory reference range
Lactate dehydrogenase Greater than 1.5 times the upper limit of laboratory reference range Neutrophils Greater than upper limit of laboratory reference range
    Platelets Greater than upper limit of laboratory reference range

Median overall survival

MSKCC risk group

Prognostic factors

Median overall survivalr (months)

Favourable 0 29.6
Intermediate 1 or 2 13.8
Poor 3 or more 4.9

IMDC risk group

Prognostic factors

Median overall survivalr (months)

Favourable 0 43.2
Intermediate 1 or 2 22.5
Poor 3 or more 7.8

While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3053

25 May 2019